{"id":4885152563259,"title":"Metagenics Bio Absorb PEA 42 caps","handle":"metagenics-bio-absorb-pea-42-capsules-vegecaps","description":"\u003ch3\u003e\u003cem\u003ePEA (Palmitoylethanolamide) With Endocannabinoid Action High Strength, Enhanced Absorption For Nerve Pain.\u003c\/em\u003e\u003c\/h3\u003e\n\u003ch2\u003eMetagenics Bio Absorb PEA 42 capsules (VegeCaps) \u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eHighly bioavailable (Palmitoylethanolamide) PEA for enhanced and superior absorption, using Levagen+ delivery system.\u003c\/li\u003e\n\u003cli\u003eExerts endocannabinoid-like actions, providing analgesic, neuroprotective and anti-inflammatory support.\u003c\/li\u003e\n\u003cli\u003eClinically trialled, sustainably sourced PEA for pain relief, including nerve pain in a convenient capsule form.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eMetagenics Bio Absorb PEA available in Size: 42 VegeCaps\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMetagenics Bio Absorb PEA is free from animal products, dairy protein, lactose, eggs, gluten, wheat, nuts, and soy protein. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMetagenics Bio Absorb PEA\u003c\/span\u003e\u003cspan\u003e is free from artificial colours, flavours and preservatives. RSPO (Roundtable on Sustainable Palm Oil) certified.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003c!-- TABS --\u003e\n\u003ch5\u003eDirections\u003c\/h5\u003e\n\u003ch2\u003eDirections: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cp\u003eTake 1 capsule twice daily, or as directed by your healthcare professional.\u003c\/p\u003e\n\u003ch5\u003eProduct Video\u003c\/h5\u003e\n\u003ch2\u003eProduct Video: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cstyle\u003e\u003c!--\n.embed-container { position: relative; padding-bottom: 56.25%; height: 0; overflow: hidden; max-width: 100%; } .embed-container iframe, .embed-container object, .embed-container embed { position: absolute; top: 0; left: 0; width: 100%; height: 100%; }\n--\u003e\u003c\/style\u003e\n\u003cdiv class=\"embed-container\"\u003e\u003ciframe src=\"https:\/\/player.vimeo.com\/video\/414968499\" allowfullscreen=\"\" mozallowfullscreen=\"\" webkitallowfullscreen=\"\" frameborder=\"0\"\u003e\u003c\/iframe\u003e\u003c\/div\u003e\n\u003ch5\u003eBenefits\u003c\/h5\u003e\n\u003ch2\u003eBenefits: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eMetagenics Bio Absorb PEA uses Levagen+ based PEA for improved bioavailability of PEA with human clinical research confirming 70% greater absorption compared to standard PEA (Figure 1).\u003c\/strong\u003e Figure 2 outlines how Levagen+ water dispersion technology overcomes the poor water solubility nature of PEA to improve absorption in the gastrointestinal system. Even with micronisation* (which reduces particle size) PEA is still lipohilic, causing aggregation and absorption at the hydrophilic gastrointestinal mucosal layer. Levagen+ prevents aggregation, while increasing hydrophilic capabilities of PEA molecules, thus improving absorption, making Bio Absorb PEA a clinically effective solution for patients requiring greater efficacy for pain relief and longer lasting benefits in the body. Figure 3 outlines key difference between Levagen+ PEA to micronised forms.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePalmitoylethanolamide (PEA) is an endocannabinoid-like lipid mediator influencing a variety of receptors and immune cells to provide antineuroinflammatory, analgesic and neuroprotective actions.\u003c\/strong\u003e PEA is found in certain foods and is endogenously produced in the body,1 with levels declining during chronic disease, tissue damage, inflammation, pain syndromes and ageing.2 PEA is associated with the endocannabinoid system (ECS) and key bioactive endocannabinoids, anandamide (AEA) and 2- arachidonoylglycerol (2-AG).3 The ECS regulates and balances an array of physiological functions in the body4 and imbalances may contribute to the development of several pathological  conditions.5,6,7 PEA supports the ECS directly by modulating endocannabinoid signalling and indirectly by activating (known as the entourage effect) cannabinoid receptors.8,9,10\u003c\/p\u003e\n\u003cdiv style=\"text-align: center;\"\u003e\u003cimg height=\"600x600\" width=\"600x600\" style=\"float: none;\" alt=\"Bio Absorb PEA Figure 1 at HealthMasters\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/files\/Bio_Absorb_PEA_Figure_1_10_off_RRP_at_HealthMasters_600x600.jpg?v=1588923937\"\u003e\u003c\/div\u003e\n\u003cp style=\"text-align: center;\"\u003e\u003cstrong\u003ePEA is extensively researched, with over 35 published human clinical trials to date. Given the current crises in pain management, including side effects and poor response to treatment, Bio Absorb PEA offers a clinically relevant and safe solution for patients in managing a variety of issues.11\u003c\/strong\u003e Key clinical applications include acute pain issues and chronic neuropathic pain conditions,12 as well as nervous system disorders, nerve damage or injury that may be contributing to pinched or compressed nerves (i.e. sciatica and carpal tunnel syndrome), nerve pressure and\/or heightened sensitivity and reactivity to pain.13,14,15,16,17 \u003c\/p\u003e\n\u003cdiv style=\"text-align: center;\"\u003e\u003cimg height=\"600x600\" width=\"600x600\" style=\"float: none;\" alt=\"Bio Absorb PEA Figure 2 at HealthMasters\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/files\/Bio_Absorb_PEA_Figure_2_10_off_RRP_at_HealthMasters_600x600.jpg?v=1588924004\"\u003e\u003c\/div\u003e\n\u003cdiv style=\"text-align: center;\"\u003e\u003cimg height=\"600x600\" width=\"600x600\" style=\"float: none;\" alt=\"Bio Absorb PEA Figure 3 at HealthMasters\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/files\/Bio_Absorb_PEA_Figure_3_10_off_RRP_at_HealthMasters_600x600.jpg?v=1588924090\"\u003e\u003c\/div\u003e\n\u003cstyle\u003e\u003c!--\n.embed-container { position: relative; padding-bottom: 56.25%; height: 0; overflow: hidden; max-width: 100%; } .embed-container iframe, .embed-container object, .embed-container embed { position: absolute; top: 0; left: 0; width: 100%; height: 100%; }\n--\u003e\u003c\/style\u003e\n\u003cdiv class=\"embed-container\"\u003e\u003ciframe src=\"https:\/\/player.vimeo.com\/video\/414968499\" allowfullscreen=\"\" mozallowfullscreen=\"\" webkitallowfullscreen=\"\" frameborder=\"0\"\u003e\u003c\/iframe\u003e\u003c\/div\u003e\n\u003ch5\u003eIngredients\u003c\/h5\u003e\n\u003ch2\u003eIngredients: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eEach Bio Absorb PEA capsule contains:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePalmidrol (Palmitoylethanolamide)\u003c\/td\u003e\n\u003ctd\u003e300mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e(Levagen+)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eBio Absorb PEA is free from animal products, dairy protein, lactose, eggs, gluten, wheat, nuts, and soy protein. Bio Absorb PEA is free from artificial colours, flavours and preservatives. RSPO (Roundtable on Sustainable Palm Oil) certified.\u003c\/p\u003e\n\u003cp\u003eLevagen+ is a trademark of Gencor.\u003c\/p\u003e\n\u003cp\u003eMetagenics products use sustainable produced palm oil, which does not harm local animals in its production. It encompasses criteria for legal, economically viable, environmentally appropriate and socially beneficial management and operations of palm oil plantations (RSPO certified).\u003c\/p\u003e\n\u003cp\u003ePalm oil is derived from the inner flesh of the fruit of the oil palm Elgeis guineensis, and is not the same as palm kernel oil which is derived from the outer coat of the palm fruit from the same tree. Palm oil contains less saturated fat than butter and contains no trans-fat, therefore the literature surrounding the use of palm oil is quite mixed. \u003c\/p\u003e\n\u003cp\u003eWith respect to the palm oil used in Metagenics Bio Absorb PEA - the manufacturing process and purification of the product does not result in the same mechanistic action of palm oil on its own, thus it does not potentiate a negative effect on the body.\u003c\/p\u003e\n\u003ch5\u003eWarnings\u003c\/h5\u003e\n\u003ch2\u003eWarnings: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cp\u003eThis medicine is not to be used for more than 21 consecutive days, and may interact with other prescription analgesic medicines. Suitable for individuals 18 years and over.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhy is there a 21-Day Warning for Bio Absorb PEA? Is it safe for me to take long term?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Therapeutic Goods Association (TGA) mandates a 21-day warning be placed on all listed PEA product labels. In listing this medicine, 17 clinical studies were provided to the TGA, of these, only three were conducted in ‘healthy participants’ with the maximum duration of these studies being 21 days, hence these three studies were considered by the TGA. \u003c\/p\u003e\n\u003cp\u003eNumerous other studies exist which used PEA over three months with-out negative effects. See References Tab for 256 references relating to PEA.\u003c\/p\u003e\n\u003cp\u003eAlways read the label. Use only as directed. If symptoms persist consult your healthcare professional.\u003c\/p\u003e\n\u003ch5\u003eStorage\u003c\/h5\u003e\n\u003ch2\u003eStorage: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cp\u003eStore below 25°C\u003c\/p\u003e\n\u003ch5\u003eReferences\u003c\/h5\u003e\n\u003ch2\u003eReferences: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cp\u003e[1] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[2] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[3] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[4] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[5] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[6] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[7] Grotenhermen F. Cannabinoids and the endocannabinoid system. Cannabinoids. 2006;1(1):10-4.\u003c\/p\u003e\n\u003cp\u003e[8] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[9] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[10] Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016 Apr 1;79(7):516-25. doi: 10.1016\/j.biopsych.2015.07.028.\u003c\/p\u003e\n\u003cp\u003e[11] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[12] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[13] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162-73. doi: 10.1016\/S1474-4422(14)70251-0.\u003c\/p\u003e\n\u003cp\u003e[14] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[15] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[16] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[17] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[18] Marcucci M, Germini F, Coerezza A, Andreinetti L, Bellintani L, Nobili A, et al. Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1randomized trials. Trials. 2016 Jul 29;17:369. doi: 10.1186\/s13063-016-1496-9.\u003c\/p\u003e\n\u003cp\u003e[19] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[20] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[21] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[22] Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat. 2014;2014:854560. doi: 10.1155\/2014\/854560.\u003c\/p\u003e\n\u003cp\u003e[23] Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20. PMID: 22229320.\u003c\/p\u003e\n\u003cp\u003e[24] Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-42. doi: 10.2147\/JPR.S32143.\u003c\/p\u003e\n\u003cp\u003e[25] Assini A, Laricchia D, Pizzo R, Pandolfini L, Belletti M, Colucci M, et al. The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide: P1577. Eur J Neurol. 2010 Sep 17;12(3):295-295.\u003c\/p\u003e\n\u003cp\u003e[26] Guida G, De Martino M, De Fabiani A, Canterieri L, Alexandre A, Vassallo GM, et al. Palmitoylethanolamide (Normast®) in chronic neuropathic pain due to compression lumbociatalgia: a multicenter clinical study. DOLOR. 2010:25(1):35-42.\u003c\/p\u003e\n\u003cp\u003e[27] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[28] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[29] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[30] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[31] Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, et al. Effectiveness of the association micronized N-palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):82-6. doi: 10.1016\/j.ejogrb.2011.04.011.\u003c\/p\u003e\n\u003cp\u003e[32] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[33] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[34] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[35] Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death Dis. 2014 Sep 11;5:e1419. doi: 10.1038\/cddis.2014.376.\u003c\/p\u003e\n\u003cp\u003e[36] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[37] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[38] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[39] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[40] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[41] Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111\/bcp.13020.\u003c\/p\u003e\n\u003cp\u003e[42] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[43] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[44] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[45] Domínguez CM, Martín AD, Ferrer FG, Puertas MI, Muro AL, González JM, et al. N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manag. 2012 Mar;2(2):119-24. doi:10.2217\/pmt.12.5.\u003c\/p\u003e\n\u003cp\u003e[46] Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E, et al. Micronized\/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation. 2014 Aug 28;11:136. doi: 10.1186\/s12974-014-0136-0.\u003c\/p\u003e\n\u003cp\u003e[47] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[48] Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol. 2016 Apr;173(7):1154-62. doi: 10.1111\/bph.13084.\u003c\/p\u003e\n\u003cp\u003e[49] Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017 Jul;20(5):353-362. PMID: 28727699.\u003c\/p\u003e\n\u003cp\u003e[50] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[51] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[52] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[53] Ambrosino P, Soldovieri MV, Russo C, Taglialatela M. Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol. 2013 Mar;168(6):1430-44. doi:10.1111\/bph.12029.\u003c\/p\u003e\n\u003cp\u003e[54] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[55] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[56] Keppel Hesselink JM, de Boer T, Witkamp RF. Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. Int J Inflam. 2013;2013:151028. doi: 10.1155\/2013\/151028.\u003c\/p\u003e\n\u003cp\u003e[57] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[58] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[59] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[60] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[61] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[62] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[63] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[64] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[65] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[66] Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017 Jun;174(11):1349-1365. doi: 10.1111\/bph.13580.\u003c\/p\u003e\n\u003cp\u003e[67] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[68] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[69] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:0.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[70] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[71] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[72] Beggiato S, Tomasini MC, Ferraro L. Palmitoylethanolamide (PEA) as a potential therapeutic agent in Alzheimer's disease. Front Pharmacol. 2019 Jul 24;10:821. doi: 10.3389\/fphar.2019.00821.\u003c\/p\u003e\n\u003cp\u003e[73] Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111\/bcp.13020.\u003c\/p\u003e\n\u003cp\u003e[74] Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111\/bcp.13020.\u003c\/p\u003e\n\u003cp\u003e[75] Briskey D, Mallard AR, Rao A. Increased absorption of palmitoylethanolamide using a novel dispersion technology system (LipiSperse®).J Nut Food Sci. 2020 May;5(2):1-6. doi:10.36648\/nutraceuticals.5.2.3\u003c\/p\u003e\n\u003cp\u003e[76] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[77] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[78] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[79] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[80] Grotenhermen F. Cannabinoids and the endocannabinoid system. Cannabinoids. 2006;1(1):10-4.\u003c\/p\u003e\n\u003cp\u003e[81] Grotenhermen F. Cannabinoids and the endocannabinoid system. Cannabinoids. 2006;1(1):10-4.\u003c\/p\u003e\n\u003cp\u003e[82] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[83] Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets. 2009 Dec;8(6):403-21. PMID: 19839937.\u003c\/p\u003e\n\u003cp\u003e[84] Cassano T, Calcagnini S, Pace L, De Marco F, Romano A, Gaetani S. Cannabinoid receptor 2 signalling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target. Front Neurosci. 2017 Feb 2;11:30. doi:10.3389\/fnins.2017.00030.\u003c\/p\u003e\n\u003cp\u003e[85] Cassano T, Calcagnini S, Pace L, De Marco F, Romano A, Gaetani S. Cannabinoid receptor 2 signalling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target. Front Neurosci. 2017 Feb 2;11:30. doi:10.3389\/fnins.2017.00030.\u003c\/p\u003e\n\u003cp\u003e[86] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[87] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[88] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[89] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[90] Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol. 2016 Apr;173(7):1154-62. doi: 10.1111\/bph.13084.\u003c\/p\u003e\n\u003cp\u003e[91] Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017 Jun;174(11):1349-1365. doi: 10.1111\/bph.13580.\u003c\/p\u003e\n\u003cp\u003e[92] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[93] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[94] Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol. 2016 Apr;173(7):1154-62. doi: 10.1111\/bph.13084.\u003c\/p\u003e\n\u003cp\u003e[95] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[96] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[97] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[98] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[99] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[100] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[101] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[102] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[103] Ambrosino P, Soldovieri MV, Russo C, Taglialatela M. Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol. 2013 Mar;168(6):1430-44. doi: 10.1111\/bph.12029.\u003c\/p\u003e\n\u003cp\u003e[104] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[105] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[106] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[107] Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol. 2016 Apr;173(7):1154-62. doi: 10.1111\/bph.13084.\u003c\/p\u003e\n\u003cp\u003e[108] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[109] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[110] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[111] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[112] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[113] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[114] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[115] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[116] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[117] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[118] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[119] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[120] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[121] Beggiato S, Tomasini MC, Ferraro L. Palmitoylethanolamide (PEA) as a potential therapeutic agent in Alzheimer's disease. Front Pharmacol. 2019 Jul 24;10:821. doi: 10.3389\/fphar.2019.00821.\u003c\/p\u003e\n\u003cp\u003e[122] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[123] Beggiato S, Tomasini MC, Ferraro L. Palmitoylethanolamide (PEA) as a potential therapeutic agent in Alzheimer's disease. Front Pharmacol. 2019 Jul 24;10:821. doi: 10.3389\/fphar.2019.00821.\u003c\/p\u003e\n\u003cp\u003e[124] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[125] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[126] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[127] Stochino Loi E, Pontis A, Cofelice V, Pirarba S, Fais MF, Daniilidis A, et al. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide\/polydatin on chronic pelvic pain and quality of life in endometriosis patients: an open-label pilot study. Int J Womens Health. 2019 Aug 12;11:443-449. doi: 10.2147\/IJWH.S204275.\u003c\/p\u003e\n\u003cp\u003e[128] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[129] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[130] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[131] Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017 Jul;20(5):353-362. PMID: 28727699.\u003c\/p\u003e\n\u003cp\u003e[132] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[133] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[134] Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C, et al. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20. PMID: 22229320.\u003c\/p\u003e\n\u003cp\u003e[135] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[136] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[137] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[138] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[139] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[140] Zhang F, Nance E, Alnasser Y, Kannan R, Kannan S. Microglial migration and interactions with dendrimer nanoparticles are altered in the presence of neuroinflammation. J Neuroinflammation. 2016 Mar 22;13(1):65. doi: 10.1186\/s12974-016-0529-3.\u003c\/p\u003e\n\u003cp\u003e[141] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[142] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[143] Pluvinage JV, Haney MS, Smith BAH, Sun J, Iram T, Bonanno L, et al. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature. 2019 Apr;568(7751):187-192. doi: 10.1038\/s41586-019-1088-4.\u003c\/p\u003e\n\u003cp\u003e[144] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[145] Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017 Jul;20(5):353-362. PMID: 28727699.\u003c\/p\u003e\n\u003cp\u003e[146] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[147] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[148] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[149] Alshelh Z, Mills EP, Kosanovic D, Di Pietro F, Macey PM, Vickers ER, et al. Effects of the glial modulator palmitoylethanolamide on chronic pain intensity and brain function. J Pain Res. 2019 Aug 2;12:2427-2439. doi: 10.2147\/JPR.S209657.\u003c\/p\u003e\n\u003cp\u003e[150] Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death Dis. 2014 Sep 11;5:e1419. doi: 10.1038\/cddis.2014.376.\u003c\/p\u003e\n\u003cp\u003e[151] Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death Dis. 2014 Sep 11;5:e1419. doi: 10.1038\/cddis.2014.376.\u003c\/p\u003e\n\u003cp\u003e[152] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[153] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[154] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[155] Hernandez-Rabaza V, Cabrera-Pastor A, Taoro-Gonzalez L, Gonzalez-Usano A, Agusti A, Balzano T, et al. Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia. J Neuroinflammation. 2016;13(1):83. Published 2016 Apr 18. doi:10.1186\/s12974-016-0549-z.\u003c\/p\u003e\n\u003cp\u003e[156] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[157] Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20. PMID: 22229320.\u003c\/p\u003e\n\u003cp\u003e[158] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[159] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[160] Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat. 2014;2014:854560. doi: 10.1155\/2014\/854560.\u003c\/p\u003e\n\u003cp\u003e[161] Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-42. doi: 10.2147\/JPR.S32143.\u003c\/p\u003e\n\u003cp\u003e[162] Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-42. doi: 10.2147\/JPR.S32143.\u003c\/p\u003e\n\u003cp\u003e[163] Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20. PMID: 22229320.\u003c\/p\u003e\n\u003cp\u003e[164] Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-42. doi: 10.2147\/JPR.S32143.\u003c\/p\u003e\n\u003cp\u003e[165] Faig-Martí J, Martínez-Catassús A. Use of palmitoylethanolamide in carpal tunnel syndrome: a prospective randomized study. J Orthop Traumatol. 2017 Dec;18(4):451-455. doi: 10.1007\/s10195-017-0453-z.\u003c\/p\u003e\n\u003cp\u003e[166] Assini A, Laricchia D, Pizzo R, Pandolfini L, Belletti M, Colucci M, et al. The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide: P1577. Eur J Neurol. 2010 Sep 17;12(3):295-295.\u003c\/p\u003e\n\u003cp\u003e[167] Guida G, De Martino M, De Fabiani A, Canterieri L, Alexandre A, Vassallo GM, et al. Palmitoylethanolamide (Normast®) in chronic neuropathic pain due to compression lumbociatalgia: a multicenter clinical study. DOLOR. 2010:25(1):35-42.\u003c\/p\u003e\n\u003cp\u003e[168] Domínguez CM, Martín AD, Ferrer FG, Puertas MI, Muro AL, González JM, et al. N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manag. 2012 Mar;2(2):119-24. doi:10.2217\/pmt.12.5.\u003c\/p\u003e\n\u003cp\u003e[169] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[170] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[171] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[172] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi: 10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[173] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi: 10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[174] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[175] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[176] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[177] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[178] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[179] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[180] Stochino Loi E, Pontis A, Cofelice V, Pirarba S, Fais MF, Daniilidis A, et al. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide\/polydatin on chronic pelvic pain and quality of life in endometriosis patients: an open-label pilot study. Int J Womens Health. 2019 Aug 12;11:443-449. doi: 10.2147\/IJWH.S204275.\u003c\/p\u003e\n\u003cp\u003e[181] Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, et al. Effectiveness of the association micronized N-palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):82-6. doi: 10.1016\/j.ejogrb.2011.04.011.\u003c\/p\u003e\n\u003cp\u003e[182] Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, et al. Effectiveness of the association micronized N-palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):82-6. doi: 10.1016\/j.ejogrb.2011.04.011.\u003c\/p\u003e\n\u003cp\u003e[183] Stochino Loi E, Pontis A, Cofelice V, Pirarba S, Fais MF, Daniilidis A, et al. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide\/polydatin on chronic pelvic pain and quality of life in endometriosis patients: an open-label pilot study. Int J Womens Health. 2019 Aug 12;11:443-449. doi: 10.2147\/IJWH.S204275.\u003c\/p\u003e\n\u003cp\u003e[184] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[185] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[186] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[187] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[188] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[189] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[190] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[191] Calabrò RS, Naro A, De Luca R, Leonardi S, Russo M, Marra A, et al. PEALut efficacy in mild cognitive impairment: evidence from a SPECT case study. Aging Clin Exp Res. 2016 Dec;28(6):1279-1282. 2016 Jan 28. PMID: 26820462.\u003c\/p\u003e\n\u003cp\u003e[192] Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death Dis. 2014 Sep 11;5:e1419. doi: 10.1038\/cddis.2014.376.\u003c\/p\u003e\n\u003cp\u003e[193] Masek K, Perlík F, Klíma J, Kahlich R. Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur J Clin Pharmacol. 1974;7(6):415–419. doi:10.1007\/bf00560353.\u003c\/p\u003e\n\u003cp\u003e[194] Antonucci N, Cirillo A, Siniscalco D. Beneficial effects of palmitoylethanolamide on expressive language, cognition, and behaviors in autism: a report of two cases. Case Rep Psychiatry. 2015;2015:325061. doi:10.1155\/2015\/325061.\u003c\/p\u003e\n\u003cp\u003e[195] Caltagirone C, Cisari C, Schievano C, Di Paola R, Cordaro M, Bruschetta G et al. Co-ultramicronized palmitoylethanolamide\/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res. 2016 Feb;7(1):54-69. doi: 10.1007\/s12975-015-0440-8.\u003c\/p\u003e\n\u003cp\u003e[196] Mallard A, Briskey D, Richards A, Mills D, Rao A. The effect of orally dosed Levagen+™(palmitoylethanolamide) on exercise recovery in healthy males—a double-blind, randomized, placebo-controlled study. Nutrients. 2020 Mar;12(3):596.\u003c\/p\u003e\n\u003cp\u003e[197] Calabrò RS, Bramanti P. Occipital neuralgia responding to palmitoylethanolamide. Headache. 2017 Nov;57(10):E23-E24. doi: 10.1111\/head.12136.\u003c\/p\u003e\n\u003cp\u003e[198] Passavanti MB, Fiore M, Sansone P, Aurilio C, Pota V, Barbarisi M, et al. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms. BMC Anesthesiol. 2017 Dec 19;17(1):171. doi: 10.1186\/s12871-017-0461-9.\u003c\/p\u003e\n\u003cp\u003e[199] Ghazizadeh-Hashemi M, Ghajar A, Shalbafan MR, Ghazizadeh-Hashemi F, Afarideh M, Malekpour F, et al. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. J Affect Disord. 2018 May;232:127-133. doi:10.1016\/j.jad.2018.02.057.\u003c\/p\u003e\n\u003cp\u003e[200] Strobbe E, Cellini M, Campos EC. Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study. Invest Ophthalmol. 2013 Feb 1;54(2):968-73.\u003c\/p\u003e\n\u003cp\u003e[201] Bacci C, Cassetta G, Emanuele B, Berengo M. Randomized split-mouth study on postoperative effects of palmitoylethanolamide for impacted lower third molar surgery. ISRN Surg. 2011;2011:917350. doi: 10.5402\/2011\/917350.\u003c\/p\u003e\n\u003cp\u003e[202] Murina F, Graziottin A, Felice R, Radici G, Tognocchi C. Vestibulodynia: synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation. J Low Genit Tract Dis. 2013 Apr;17(2):111-6. doi: 10.1097\/LGT.0b013e3182652316.\u003c\/p\u003e\n\u003cp\u003e[203] Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437–442. doi:10.2147\/JPR.S32143.\u003c\/p\u003e\n\u003cp\u003e[204] Chirchiglia D, Chirchiglia P, Marotta R, Gallelli L. Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome. Int Med Case Rep J. 2019 Feb 15;12:39–42. doi:10.2147\/IMCRJ.S194403.\u003c\/p\u003e\n\u003cp\u003e[205] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[206] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[207] Passavanti MB, Fiore M, Sansone P, Aurilio C, Pota V, Barbarisi M, et al. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms. BMC Anesthesiol. 2017 Dec 19;17(1):171. doi: 10.1186\/s12871-017-0461-9.\u003c\/p\u003e\n\u003cp\u003e[208] Ghazizadeh-Hashemi M, Ghajar A, Shalbafan MR, Ghazizadeh-Hashemi F, Afarideh M, Malekpour F, et al. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. J Affect Disord. 2018 May;232:127-133. doi:10.1016\/j.jad.2018.02.057.\u003c\/p\u003e\n\u003cp\u003e[209] Chirchiglia D, Cione E, Caroleo MC, Wang M, Di Mizio G, Faedda N, et al. Effects of add-on ultramicronized N-palmitolethanolamide in patients suffering of migraine with aura: a pilot study. Front Neurol. 2018 Aug 17;9:674. doi:10.3389\/fneur.2018.00674.\u003c\/p\u003e\n\u003cp\u003e[210] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[211] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[212] Chirchiglia D, Della Torre A, Signorelli F, Volpentesta G, Guzzi G, Stroscio CA, et al. Administration of palmitoylethanolamide in combination with topiramate in the preventive treatment of nummular headache. Int Med Case Rep J. 2016 Jul 18;9:193–195. doi:10.2147\/IMCRJ.S106323.\u003c\/p\u003e\n\u003cp\u003e[213] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[214] Keppel Hesselink JM, de Boer T, Witkamp RF. Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common Cold. Int J Inflam. 2013;2013:151028. doi: 10.1155\/2013\/151028.\u003c\/p\u003e\n\u003cp\u003e[215] Assini A, Laricchia D, Pizzo R, Pandolfini L, Belletti M, Colucci M, et al. The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide: P1577. Eur J Neurol. 2010 Sep 17;12(3):295-295.\u003c\/p\u003e\n\u003cp\u003e[216] Coraci D, Loreti C, Granata G, Arezzo MF, Padua L. Carpal tunnel syndrome treatment with palmitoylethanolamide: neurophysiology and ultrasound show small changes in the median nerve. Rheumatol Int. 2018 Jul;38(7):1307-1309. doi:10.1007\/s00296-018-4064-7.\u003c\/p\u003e\n\u003cp\u003e[217] Faig-Martí J, Martínez-Catassús A. Use of palmitoylethanolamide in carpal tunnel syndrome: a prospective randomized study. J Orthop Traumatol. 2017 Dec;18(4):451-455. doi: 10.1007\/s10195-017-0453-z.\u003c\/p\u003e\n\u003cp\u003e[218] Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med. 2011 Apr;102(2):141-7. PMID: 21483401.\u003c\/p\u003e\n\u003cp\u003e[219] Calabrò RS, Naro A, De Luca R, Leonardi S, Russo M, Marra A, et al. PEALut efficacy in mild cognitive impairment: evidence from a SPECT case study. Aging Clin Exp Res. 2016 Dec;28(6):1279-1282. 2016 Jan 28. PMID: 26820462.\u003c\/p\u003e\n\u003cp\u003e[220] Ghazizadeh-Hashemi M, Ghajar A, Shalbafan MR, Ghazizadeh-Hashemi F, Afarideh M, Malekpour F, et al. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. J Affect Disord. 2018 May;232:127-133. doi:10.1016\/j.jad.2018.02.057.\u003c\/p\u003e\n\u003cp\u003e[221] Tartaglia E, Armentano M, Giugliano B, Sena T, Giuliano P, Loffredo C, et al. Effectiveness of the association N-palmitoylethanolamine and transpolydatin in the treatment of primary dysmenorrhea. J Pediatr Adolesc Gynecol. 2015 Dec;28(6):447-50. doi: 10.1016\/j.jpag.2014.12.011.\u003c\/p\u003e\n\u003cp\u003e[222] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[223] Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat. 2014;2014:854560. doi: 10.1155\/2014\/854560.\u003c\/p\u003e\n\u003cp\u003e[224] Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, et al. Effectiveness of the association micronized N-palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):82-6. doi: 10.1016\/j.ejogrb.2011.04.011.\u003c\/p\u003e\n\u003cp\u003e[225] Giugliano E, Cagnazzo E, Soave I, Lo Monte G, Wenger JM, Marci R. The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain. Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):209-13. doi: 10.1016\/j.ejogrb.2013.01.009.\u003c\/p\u003e\n\u003cp\u003e[226] Di Francesco A, Pizzigallo D. Use of micronized palmitoylethanolamide and trans-polydatin in chronic pelvic pain associated with endometriosis: an open-label study. Giornale Italiano di Ostetricia e Ginecologia CIC Edizioni Internazionali.2014 May 30;36(2):353-358.\u003c\/p\u003e\n\u003cp\u003e[227] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[228] Schweiger V, Martini A, Bellamoli P, Donadello K, Schievano C, Balzo GD, et al. Ultramicronized palmitoylethanolamide(um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): retrospective observational study on 407 patients. CNS Neurol Disord Drug Targets. 2019;18(4):326-333. doi: 10.2174\/1871527318666190227205359.\u003c\/p\u003e\n\u003cp\u003e[229] Keppel Hesselink JM, Costagliola C, Fakhry J, Kopsky DJ. Palmitoylethanolamide, a natural retinoprotectant: its putative relevance for the treatment of glaucoma and diabetic retinopathy. J Ophthalmol. 2015;2015:430596. doi: 10.1155\/2015\/430596.\u003c\/p\u003e\n\u003cp\u003e[230] Domínguez CM, Martín AD, Ferrer FG, Puertas MI, Muro AL, González JM, et al. N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manag. 2012 Mar;2(2):119-24. doi:10.2217\/pmt.12.5.\u003c\/p\u003e\n\u003cp\u003e[231] Passavanti MB, Fiore M, Sansone P, Aurilio C, Pota V, Barbarisi M, et al. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms. BMC Anesthesiol. 2017 Dec 19;17(1):171. doi: 10.1186\/s12871-017-0461-9.\u003c\/p\u003e\n\u003cp\u003e[232] Desio P. Combination of oxycodone and palmitoylethanolamide for low back pain treatment. AMC. 2011;1(2):62–71.\u003c\/p\u003e\n\u003cp\u003e[233] Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20. PMID: 22229320.\u003c\/p\u003e\n\u003cp\u003e[234] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[235] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[236] Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017 Jul;20(5):353-362. PMID: 28727699.\u003c\/p\u003e\n\u003cp\u003e[237] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[238] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[239] Domínguez CM, Martín AD, Ferrer FG, Puertas MI, Muro AL, González JM, et al. N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manag. 2012 Mar;2(2):119-24. doi:10.2217\/pmt.12.5.\u003c\/p\u003e\n\u003cp\u003e[240] Guida G, De Martino M, De Fabiani A, Canterieri L, Alexandre A, Vassallo GM, et al. Palmitoylethanolamide (Normast®) in chronic neuropathic pain due to compression lumbociatalgia: a multicenter clinical study. DOLOR. 2010:25(1):35-42.\u003c\/p\u003e\n\u003cp\u003e[241] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015;8:729-734. doi:10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[242] Guida G, Cantieri L, Petrosino S. Reduction of the consumption of anti‐inflammatory drugs and analgesics in the treatment of chronic neuropathic pain in patients affected by compressive lumbociatalgia and in treatment with Normast® 300 mg. Pain. Clin \u0026amp; Thera Res 2010; 25(4):227‐234.\u003c\/p\u003e\n\u003cp\u003e[243] Caltagirone C, Cisari C, Schievano C, Di Paola R, Cordaro M, Bruschetta G, et al. Co-ultramicronized palmitoylethanolamide\/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res. 2016 Feb;7(1):54-69. doi: 10.1007\/s12975-015-0440-8.\u003c\/p\u003e\n\u003cp\u003e[244] Bacci C, Cassetta G, Emanuele B, Berengo M. Randomized split-mouth study on postoperative effects of palmitoylethanolamide for impacted lower third molar surgery. ISRN Surg. 2011;2011:917350. doi: 10.5402\/2011\/917350.\u003c\/p\u003e\n\u003cp\u003e[245] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[246] Kopsky DJ, Hesselink JM. Multimodal stepped care approach with acupuncture and PPAR-α agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain. Acupunct Med. 2012 Mar;30(1):53-5. doi: 10.1136\/acupmed-2011-010119.\u003c\/p\u003e\n\u003cp\u003e[247] Murina F, Graziottin A, Felice R, Radici G, Tognocchi C. Vestibulodynia: synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation. J Low Genit Tract Dis. 2013 Apr;17(2):111-6. doi: 10.1097\/LGT.0b013e3182652316.\u003c\/p\u003e\n\u003cp\u003e[248] Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111\/bcp.13020.\u003c\/p\u003e\n\u003cp\u003e[249] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[250] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012;13(9):1121–30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[251] Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017 Jul;20(5):353-362. PMID: 28727699.\u003c\/p\u003e\n\u003cp\u003e[252] Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11–24.\u003c\/p\u003e\n\u003cp\u003e[253] Déciga-Campos M, Ramírez-Marín PM, López-Muñoz FJ. Synergistic antinociceptive interaction between palmitoylethanolamide and tramadol in the mouse formalin test. Eur J Pharmacol. 2015;765:68–74. doi:10.1016\/j.ejphar.2015.08.025.\u003c\/p\u003e\n\u003cp\u003e[254] Russo R, LoVerme J, La Rana G, D'Agostinoa G, Sassoa O, Calignano A, et al. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol. 2007;566(1-3):117–9. doi:10.1016\/j.ejphar.2007.03.007.\u003c\/p\u003e\n\u003cp\u003e[255] Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111\/bcp.13020.\u003c\/p\u003e\n\u003cp\u003e[256] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012;13(9):1121–30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003c!-- \/TABS --\u003e","published_at":"2020-05-08T17:30:54+10:00","created_at":"2020-05-08T17:34:49+10:00","vendor":"Metagenics","type":"Metagenics Naturopathic Medicines","tags":["Metagenics","Pain and Inflammation","PEA"],"price":5625,"price_min":5625,"price_max":5625,"available":true,"price_varies":false,"compare_at_price":6250,"compare_at_price_min":6250,"compare_at_price_max":6250,"compare_at_price_varies":false,"variants":[{"id":33639427670075,"title":"Default Title","option1":"Default Title","option2":null,"option3":null,"sku":"BioAbsorbPEA42caps","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"name":"Metagenics Bio Absorb PEA 42 caps","public_title":null,"options":["Default Title"],"price":5625,"weight":0,"compare_at_price":6250,"inventory_quantity":9946,"inventory_management":"shopify","inventory_policy":"deny","barcode":""}],"images":["\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-70.jpg?v=1592951958","\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-1.jpg?v=1592951958","\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-3.jpg?v=1592951958","\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-2.jpg?v=1592951958","\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/Metagenics10_offRRPatHealthMasters.jpg?v=1596757066"],"featured_image":"\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-70.jpg?v=1592951958","options":["Title"],"media":[{"alt":null,"id":9730672656542,"position":1,"preview_image":{"aspect_ratio":1.0,"height":2400,"width":2400,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-70.jpg?v=1592951954"},"aspect_ratio":1.0,"height":2400,"media_type":"image","src":"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-70.jpg?v=1592951954","width":2400},{"alt":null,"id":9730662957214,"position":2,"preview_image":{"aspect_ratio":1.0,"height":2400,"width":2400,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-1.jpg?v=1592951881"},"aspect_ratio":1.0,"height":2400,"media_type":"image","src":"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-1.jpg?v=1592951881","width":2400},{"alt":null,"id":9730662924446,"position":3,"preview_image":{"aspect_ratio":1.0,"height":2400,"width":2400,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-3.jpg?v=1592951882"},"aspect_ratio":1.0,"height":2400,"media_type":"image","src":"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-3.jpg?v=1592951882","width":2400},{"alt":null,"id":9730662989982,"position":4,"preview_image":{"aspect_ratio":1.0,"height":2400,"width":2400,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-2.jpg?v=1592951882"},"aspect_ratio":1.0,"height":2400,"media_type":"image","src":"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/MetagenicsBioAbsorbPEA42Capsules_VegeCaps_-2.jpg?v=1592951882","width":2400},{"alt":"Metagenics at HealthMasters","id":8159902171195,"position":5,"preview_image":{"aspect_ratio":0.944,"height":500,"width":472,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/Metagenics10_offRRPatHealthMasters.jpg?v=1588927411"},"aspect_ratio":0.944,"height":500,"media_type":"image","src":"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/products\/Metagenics10_offRRPatHealthMasters.jpg?v=1588927411","width":472}],"content":"\u003ch3\u003e\u003cem\u003ePEA (Palmitoylethanolamide) With Endocannabinoid Action High Strength, Enhanced Absorption For Nerve Pain.\u003c\/em\u003e\u003c\/h3\u003e\n\u003ch2\u003eMetagenics Bio Absorb PEA 42 capsules (VegeCaps) \u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eHighly bioavailable (Palmitoylethanolamide) PEA for enhanced and superior absorption, using Levagen+ delivery system.\u003c\/li\u003e\n\u003cli\u003eExerts endocannabinoid-like actions, providing analgesic, neuroprotective and anti-inflammatory support.\u003c\/li\u003e\n\u003cli\u003eClinically trialled, sustainably sourced PEA for pain relief, including nerve pain in a convenient capsule form.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eMetagenics Bio Absorb PEA available in Size: 42 VegeCaps\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMetagenics Bio Absorb PEA is free from animal products, dairy protein, lactose, eggs, gluten, wheat, nuts, and soy protein. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMetagenics Bio Absorb PEA\u003c\/span\u003e\u003cspan\u003e is free from artificial colours, flavours and preservatives. RSPO (Roundtable on Sustainable Palm Oil) certified.\u003c\/span\u003e\u003c\/p\u003e\n\n\u003c!-- TABS --\u003e\n\u003ch5\u003eDirections\u003c\/h5\u003e\n\u003ch2\u003eDirections: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cp\u003eTake 1 capsule twice daily, or as directed by your healthcare professional.\u003c\/p\u003e\n\u003ch5\u003eProduct Video\u003c\/h5\u003e\n\u003ch2\u003eProduct Video: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cstyle\u003e\u003c!--\n.embed-container { position: relative; padding-bottom: 56.25%; height: 0; overflow: hidden; max-width: 100%; } .embed-container iframe, .embed-container object, .embed-container embed { position: absolute; top: 0; left: 0; width: 100%; height: 100%; }\n--\u003e\u003c\/style\u003e\n\u003cdiv class=\"embed-container\"\u003e\u003ciframe src=\"https:\/\/player.vimeo.com\/video\/414968499\" allowfullscreen=\"\" mozallowfullscreen=\"\" webkitallowfullscreen=\"\" frameborder=\"0\"\u003e\u003c\/iframe\u003e\u003c\/div\u003e\n\u003ch5\u003eBenefits\u003c\/h5\u003e\n\u003ch2\u003eBenefits: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eMetagenics Bio Absorb PEA uses Levagen+ based PEA for improved bioavailability of PEA with human clinical research confirming 70% greater absorption compared to standard PEA (Figure 1).\u003c\/strong\u003e Figure 2 outlines how Levagen+ water dispersion technology overcomes the poor water solubility nature of PEA to improve absorption in the gastrointestinal system. Even with micronisation* (which reduces particle size) PEA is still lipohilic, causing aggregation and absorption at the hydrophilic gastrointestinal mucosal layer. Levagen+ prevents aggregation, while increasing hydrophilic capabilities of PEA molecules, thus improving absorption, making Bio Absorb PEA a clinically effective solution for patients requiring greater efficacy for pain relief and longer lasting benefits in the body. Figure 3 outlines key difference between Levagen+ PEA to micronised forms.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePalmitoylethanolamide (PEA) is an endocannabinoid-like lipid mediator influencing a variety of receptors and immune cells to provide antineuroinflammatory, analgesic and neuroprotective actions.\u003c\/strong\u003e PEA is found in certain foods and is endogenously produced in the body,1 with levels declining during chronic disease, tissue damage, inflammation, pain syndromes and ageing.2 PEA is associated with the endocannabinoid system (ECS) and key bioactive endocannabinoids, anandamide (AEA) and 2- arachidonoylglycerol (2-AG).3 The ECS regulates and balances an array of physiological functions in the body4 and imbalances may contribute to the development of several pathological  conditions.5,6,7 PEA supports the ECS directly by modulating endocannabinoid signalling and indirectly by activating (known as the entourage effect) cannabinoid receptors.8,9,10\u003c\/p\u003e\n\u003cdiv style=\"text-align: center;\"\u003e\u003cimg height=\"600x600\" width=\"600x600\" style=\"float: none;\" alt=\"Bio Absorb PEA Figure 1 at HealthMasters\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/files\/Bio_Absorb_PEA_Figure_1_10_off_RRP_at_HealthMasters_600x600.jpg?v=1588923937\"\u003e\u003c\/div\u003e\n\u003cp style=\"text-align: center;\"\u003e\u003cstrong\u003ePEA is extensively researched, with over 35 published human clinical trials to date. Given the current crises in pain management, including side effects and poor response to treatment, Bio Absorb PEA offers a clinically relevant and safe solution for patients in managing a variety of issues.11\u003c\/strong\u003e Key clinical applications include acute pain issues and chronic neuropathic pain conditions,12 as well as nervous system disorders, nerve damage or injury that may be contributing to pinched or compressed nerves (i.e. sciatica and carpal tunnel syndrome), nerve pressure and\/or heightened sensitivity and reactivity to pain.13,14,15,16,17 \u003c\/p\u003e\n\u003cdiv style=\"text-align: center;\"\u003e\u003cimg height=\"600x600\" width=\"600x600\" style=\"float: none;\" alt=\"Bio Absorb PEA Figure 2 at HealthMasters\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/files\/Bio_Absorb_PEA_Figure_2_10_off_RRP_at_HealthMasters_600x600.jpg?v=1588924004\"\u003e\u003c\/div\u003e\n\u003cdiv style=\"text-align: center;\"\u003e\u003cimg height=\"600x600\" width=\"600x600\" style=\"float: none;\" alt=\"Bio Absorb PEA Figure 3 at HealthMasters\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/2075\/8503\/files\/Bio_Absorb_PEA_Figure_3_10_off_RRP_at_HealthMasters_600x600.jpg?v=1588924090\"\u003e\u003c\/div\u003e\n\u003cstyle\u003e\u003c!--\n.embed-container { position: relative; padding-bottom: 56.25%; height: 0; overflow: hidden; max-width: 100%; } .embed-container iframe, .embed-container object, .embed-container embed { position: absolute; top: 0; left: 0; width: 100%; height: 100%; }\n--\u003e\u003c\/style\u003e\n\u003cdiv class=\"embed-container\"\u003e\u003ciframe src=\"https:\/\/player.vimeo.com\/video\/414968499\" allowfullscreen=\"\" mozallowfullscreen=\"\" webkitallowfullscreen=\"\" frameborder=\"0\"\u003e\u003c\/iframe\u003e\u003c\/div\u003e\n\u003ch5\u003eIngredients\u003c\/h5\u003e\n\u003ch2\u003eIngredients: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eEach Bio Absorb PEA capsule contains:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePalmidrol (Palmitoylethanolamide)\u003c\/td\u003e\n\u003ctd\u003e300mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e(Levagen+)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eBio Absorb PEA is free from animal products, dairy protein, lactose, eggs, gluten, wheat, nuts, and soy protein. Bio Absorb PEA is free from artificial colours, flavours and preservatives. RSPO (Roundtable on Sustainable Palm Oil) certified.\u003c\/p\u003e\n\u003cp\u003eLevagen+ is a trademark of Gencor.\u003c\/p\u003e\n\u003cp\u003eMetagenics products use sustainable produced palm oil, which does not harm local animals in its production. It encompasses criteria for legal, economically viable, environmentally appropriate and socially beneficial management and operations of palm oil plantations (RSPO certified).\u003c\/p\u003e\n\u003cp\u003ePalm oil is derived from the inner flesh of the fruit of the oil palm Elgeis guineensis, and is not the same as palm kernel oil which is derived from the outer coat of the palm fruit from the same tree. Palm oil contains less saturated fat than butter and contains no trans-fat, therefore the literature surrounding the use of palm oil is quite mixed. \u003c\/p\u003e\n\u003cp\u003eWith respect to the palm oil used in Metagenics Bio Absorb PEA - the manufacturing process and purification of the product does not result in the same mechanistic action of palm oil on its own, thus it does not potentiate a negative effect on the body.\u003c\/p\u003e\n\u003ch5\u003eWarnings\u003c\/h5\u003e\n\u003ch2\u003eWarnings: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cp\u003eThis medicine is not to be used for more than 21 consecutive days, and may interact with other prescription analgesic medicines. Suitable for individuals 18 years and over.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhy is there a 21-Day Warning for Bio Absorb PEA? Is it safe for me to take long term?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Therapeutic Goods Association (TGA) mandates a 21-day warning be placed on all listed PEA product labels. In listing this medicine, 17 clinical studies were provided to the TGA, of these, only three were conducted in ‘healthy participants’ with the maximum duration of these studies being 21 days, hence these three studies were considered by the TGA. \u003c\/p\u003e\n\u003cp\u003eNumerous other studies exist which used PEA over three months with-out negative effects. See References Tab for 256 references relating to PEA.\u003c\/p\u003e\n\u003cp\u003eAlways read the label. Use only as directed. If symptoms persist consult your healthcare professional.\u003c\/p\u003e\n\u003ch5\u003eStorage\u003c\/h5\u003e\n\u003ch2\u003eStorage: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cp\u003eStore below 25°C\u003c\/p\u003e\n\u003ch5\u003eReferences\u003c\/h5\u003e\n\u003ch2\u003eReferences: Metagenics Bio Absorb PEA\u003c\/h2\u003e\n\u003cp\u003e[1] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[2] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[3] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[4] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[5] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[6] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[7] Grotenhermen F. Cannabinoids and the endocannabinoid system. Cannabinoids. 2006;1(1):10-4.\u003c\/p\u003e\n\u003cp\u003e[8] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[9] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[10] Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016 Apr 1;79(7):516-25. doi: 10.1016\/j.biopsych.2015.07.028.\u003c\/p\u003e\n\u003cp\u003e[11] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[12] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[13] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162-73. doi: 10.1016\/S1474-4422(14)70251-0.\u003c\/p\u003e\n\u003cp\u003e[14] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[15] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[16] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[17] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[18] Marcucci M, Germini F, Coerezza A, Andreinetti L, Bellintani L, Nobili A, et al. Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1randomized trials. Trials. 2016 Jul 29;17:369. doi: 10.1186\/s13063-016-1496-9.\u003c\/p\u003e\n\u003cp\u003e[19] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[20] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[21] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[22] Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat. 2014;2014:854560. doi: 10.1155\/2014\/854560.\u003c\/p\u003e\n\u003cp\u003e[23] Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20. PMID: 22229320.\u003c\/p\u003e\n\u003cp\u003e[24] Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-42. doi: 10.2147\/JPR.S32143.\u003c\/p\u003e\n\u003cp\u003e[25] Assini A, Laricchia D, Pizzo R, Pandolfini L, Belletti M, Colucci M, et al. The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide: P1577. Eur J Neurol. 2010 Sep 17;12(3):295-295.\u003c\/p\u003e\n\u003cp\u003e[26] Guida G, De Martino M, De Fabiani A, Canterieri L, Alexandre A, Vassallo GM, et al. Palmitoylethanolamide (Normast®) in chronic neuropathic pain due to compression lumbociatalgia: a multicenter clinical study. DOLOR. 2010:25(1):35-42.\u003c\/p\u003e\n\u003cp\u003e[27] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[28] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[29] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[30] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[31] Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, et al. Effectiveness of the association micronized N-palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):82-6. doi: 10.1016\/j.ejogrb.2011.04.011.\u003c\/p\u003e\n\u003cp\u003e[32] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[33] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[34] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[35] Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death Dis. 2014 Sep 11;5:e1419. doi: 10.1038\/cddis.2014.376.\u003c\/p\u003e\n\u003cp\u003e[36] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[37] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[38] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[39] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[40] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[41] Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111\/bcp.13020.\u003c\/p\u003e\n\u003cp\u003e[42] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[43] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[44] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[45] Domínguez CM, Martín AD, Ferrer FG, Puertas MI, Muro AL, González JM, et al. N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manag. 2012 Mar;2(2):119-24. doi:10.2217\/pmt.12.5.\u003c\/p\u003e\n\u003cp\u003e[46] Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E, et al. Micronized\/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation. 2014 Aug 28;11:136. doi: 10.1186\/s12974-014-0136-0.\u003c\/p\u003e\n\u003cp\u003e[47] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[48] Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol. 2016 Apr;173(7):1154-62. doi: 10.1111\/bph.13084.\u003c\/p\u003e\n\u003cp\u003e[49] Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017 Jul;20(5):353-362. PMID: 28727699.\u003c\/p\u003e\n\u003cp\u003e[50] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[51] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[52] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[53] Ambrosino P, Soldovieri MV, Russo C, Taglialatela M. Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol. 2013 Mar;168(6):1430-44. doi:10.1111\/bph.12029.\u003c\/p\u003e\n\u003cp\u003e[54] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[55] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[56] Keppel Hesselink JM, de Boer T, Witkamp RF. Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. Int J Inflam. 2013;2013:151028. doi: 10.1155\/2013\/151028.\u003c\/p\u003e\n\u003cp\u003e[57] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[58] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[59] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[60] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[61] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[62] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[63] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[64] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[65] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[66] Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017 Jun;174(11):1349-1365. doi: 10.1111\/bph.13580.\u003c\/p\u003e\n\u003cp\u003e[67] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[68] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[69] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:0.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[70] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[71] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[72] Beggiato S, Tomasini MC, Ferraro L. Palmitoylethanolamide (PEA) as a potential therapeutic agent in Alzheimer's disease. Front Pharmacol. 2019 Jul 24;10:821. doi: 10.3389\/fphar.2019.00821.\u003c\/p\u003e\n\u003cp\u003e[73] Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111\/bcp.13020.\u003c\/p\u003e\n\u003cp\u003e[74] Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111\/bcp.13020.\u003c\/p\u003e\n\u003cp\u003e[75] Briskey D, Mallard AR, Rao A. Increased absorption of palmitoylethanolamide using a novel dispersion technology system (LipiSperse®).J Nut Food Sci. 2020 May;5(2):1-6. doi:10.36648\/nutraceuticals.5.2.3\u003c\/p\u003e\n\u003cp\u003e[76] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[77] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[78] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[79] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[80] Grotenhermen F. Cannabinoids and the endocannabinoid system. Cannabinoids. 2006;1(1):10-4.\u003c\/p\u003e\n\u003cp\u003e[81] Grotenhermen F. Cannabinoids and the endocannabinoid system. Cannabinoids. 2006;1(1):10-4.\u003c\/p\u003e\n\u003cp\u003e[82] Wang J. Glial endocannabinoid system in pain modulation. Int J Neurosci. 2019 Jan;129(1):94-100. doi: 10.1080\/00207454.2018.1503178.\u003c\/p\u003e\n\u003cp\u003e[83] Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets. 2009 Dec;8(6):403-21. PMID: 19839937.\u003c\/p\u003e\n\u003cp\u003e[84] Cassano T, Calcagnini S, Pace L, De Marco F, Romano A, Gaetani S. Cannabinoid receptor 2 signalling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target. Front Neurosci. 2017 Feb 2;11:30. doi:10.3389\/fnins.2017.00030.\u003c\/p\u003e\n\u003cp\u003e[85] Cassano T, Calcagnini S, Pace L, De Marco F, Romano A, Gaetani S. Cannabinoid receptor 2 signalling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target. Front Neurosci. 2017 Feb 2;11:30. doi:10.3389\/fnins.2017.00030.\u003c\/p\u003e\n\u003cp\u003e[86] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[87] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[88] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[89] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[90] Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol. 2016 Apr;173(7):1154-62. doi: 10.1111\/bph.13084.\u003c\/p\u003e\n\u003cp\u003e[91] Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017 Jun;174(11):1349-1365. doi: 10.1111\/bph.13580.\u003c\/p\u003e\n\u003cp\u003e[92] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[93] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[94] Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol. 2016 Apr;173(7):1154-62. doi: 10.1111\/bph.13084.\u003c\/p\u003e\n\u003cp\u003e[95] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[96] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[97] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[98] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[99] Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9).e2175. doi: 10.3390\/nu11092175.\u003c\/p\u003e\n\u003cp\u003e[100] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[101] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[102] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[103] Ambrosino P, Soldovieri MV, Russo C, Taglialatela M. Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol. 2013 Mar;168(6):1430-44. doi: 10.1111\/bph.12029.\u003c\/p\u003e\n\u003cp\u003e[104] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[105] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[106] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[107] Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol. 2016 Apr;173(7):1154-62. doi: 10.1111\/bph.13084.\u003c\/p\u003e\n\u003cp\u003e[108] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[109] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[110] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[111] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[112] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[113] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[114] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[115] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[116] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[117] Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014 Oct;19(10):1632-9. doi: 10.1016\/j.drudis.2014.06.007.\u003c\/p\u003e\n\u003cp\u003e[118] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[119] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[120] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[121] Beggiato S, Tomasini MC, Ferraro L. Palmitoylethanolamide (PEA) as a potential therapeutic agent in Alzheimer's disease. Front Pharmacol. 2019 Jul 24;10:821. doi: 10.3389\/fphar.2019.00821.\u003c\/p\u003e\n\u003cp\u003e[122] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[123] Beggiato S, Tomasini MC, Ferraro L. Palmitoylethanolamide (PEA) as a potential therapeutic agent in Alzheimer's disease. Front Pharmacol. 2019 Jul 24;10:821. doi: 10.3389\/fphar.2019.00821.\u003c\/p\u003e\n\u003cp\u003e[124] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[125] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[126] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[127] Stochino Loi E, Pontis A, Cofelice V, Pirarba S, Fais MF, Daniilidis A, et al. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide\/polydatin on chronic pelvic pain and quality of life in endometriosis patients: an open-label pilot study. Int J Womens Health. 2019 Aug 12;11:443-449. doi: 10.2147\/IJWH.S204275.\u003c\/p\u003e\n\u003cp\u003e[128] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[129] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[130] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[131] Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017 Jul;20(5):353-362. PMID: 28727699.\u003c\/p\u003e\n\u003cp\u003e[132] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[133] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[134] Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C, et al. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20. PMID: 22229320.\u003c\/p\u003e\n\u003cp\u003e[135] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015 Oct 23;8:729-34. doi: 10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[136] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[137] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[138] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[139] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[140] Zhang F, Nance E, Alnasser Y, Kannan R, Kannan S. Microglial migration and interactions with dendrimer nanoparticles are altered in the presence of neuroinflammation. J Neuroinflammation. 2016 Mar 22;13(1):65. doi: 10.1186\/s12974-016-0529-3.\u003c\/p\u003e\n\u003cp\u003e[141] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[142] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[143] Pluvinage JV, Haney MS, Smith BAH, Sun J, Iram T, Bonanno L, et al. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature. 2019 Apr;568(7751):187-192. doi: 10.1038\/s41586-019-1088-4.\u003c\/p\u003e\n\u003cp\u003e[144] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[145] Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017 Jul;20(5):353-362. PMID: 28727699.\u003c\/p\u003e\n\u003cp\u003e[146] Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017 Mar 23;7(1):375. doi: 10.1038\/s41598-017-00342-1.\u003c\/p\u003e\n\u003cp\u003e[147] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[148] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[149] Alshelh Z, Mills EP, Kosanovic D, Di Pietro F, Macey PM, Vickers ER, et al. Effects of the glial modulator palmitoylethanolamide on chronic pain intensity and brain function. J Pain Res. 2019 Aug 2;12:2427-2439. doi: 10.2147\/JPR.S209657.\u003c\/p\u003e\n\u003cp\u003e[150] Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death Dis. 2014 Sep 11;5:e1419. doi: 10.1038\/cddis.2014.376.\u003c\/p\u003e\n\u003cp\u003e[151] Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death Dis. 2014 Sep 11;5:e1419. doi: 10.1038\/cddis.2014.376.\u003c\/p\u003e\n\u003cp\u003e[152] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[153] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[154] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[155] Hernandez-Rabaza V, Cabrera-Pastor A, Taoro-Gonzalez L, Gonzalez-Usano A, Agusti A, Balzano T, et al. Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia. J Neuroinflammation. 2016;13(1):83. Published 2016 Apr 18. doi:10.1186\/s12974-016-0549-z.\u003c\/p\u003e\n\u003cp\u003e[156] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[157] Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20. PMID: 22229320.\u003c\/p\u003e\n\u003cp\u003e[158] Donvito G, Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice. J Pharmacol Exp Ther. 2016 Nov;359(2):310-318. PMID: 27608657.\u003c\/p\u003e\n\u003cp\u003e[159] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[160] Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat. 2014;2014:854560. doi: 10.1155\/2014\/854560.\u003c\/p\u003e\n\u003cp\u003e[161] Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-42. doi: 10.2147\/JPR.S32143.\u003c\/p\u003e\n\u003cp\u003e[162] Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-42. doi: 10.2147\/JPR.S32143.\u003c\/p\u003e\n\u003cp\u003e[163] Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20. PMID: 22229320.\u003c\/p\u003e\n\u003cp\u003e[164] Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-42. doi: 10.2147\/JPR.S32143.\u003c\/p\u003e\n\u003cp\u003e[165] Faig-Martí J, Martínez-Catassús A. Use of palmitoylethanolamide in carpal tunnel syndrome: a prospective randomized study. J Orthop Traumatol. 2017 Dec;18(4):451-455. doi: 10.1007\/s10195-017-0453-z.\u003c\/p\u003e\n\u003cp\u003e[166] Assini A, Laricchia D, Pizzo R, Pandolfini L, Belletti M, Colucci M, et al. The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide: P1577. Eur J Neurol. 2010 Sep 17;12(3):295-295.\u003c\/p\u003e\n\u003cp\u003e[167] Guida G, De Martino M, De Fabiani A, Canterieri L, Alexandre A, Vassallo GM, et al. Palmitoylethanolamide (Normast®) in chronic neuropathic pain due to compression lumbociatalgia: a multicenter clinical study. DOLOR. 2010:25(1):35-42.\u003c\/p\u003e\n\u003cp\u003e[168] Domínguez CM, Martín AD, Ferrer FG, Puertas MI, Muro AL, González JM, et al. N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manag. 2012 Mar;2(2):119-24. doi:10.2217\/pmt.12.5.\u003c\/p\u003e\n\u003cp\u003e[169] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[170] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[171] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[172] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi: 10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[173] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi: 10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[174] Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017 Sep;4(3):210-218. doi:10.5152\/eurjrheum.2017.17025.\u003c\/p\u003e\n\u003cp\u003e[175] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[176] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[177] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[178] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[179] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[180] Stochino Loi E, Pontis A, Cofelice V, Pirarba S, Fais MF, Daniilidis A, et al. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide\/polydatin on chronic pelvic pain and quality of life in endometriosis patients: an open-label pilot study. Int J Womens Health. 2019 Aug 12;11:443-449. doi: 10.2147\/IJWH.S204275.\u003c\/p\u003e\n\u003cp\u003e[181] Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, et al. Effectiveness of the association micronized N-palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):82-6. doi: 10.1016\/j.ejogrb.2011.04.011.\u003c\/p\u003e\n\u003cp\u003e[182] Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, et al. Effectiveness of the association micronized N-palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):82-6. doi: 10.1016\/j.ejogrb.2011.04.011.\u003c\/p\u003e\n\u003cp\u003e[183] Stochino Loi E, Pontis A, Cofelice V, Pirarba S, Fais MF, Daniilidis A, et al. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide\/polydatin on chronic pelvic pain and quality of life in endometriosis patients: an open-label pilot study. Int J Womens Health. 2019 Aug 12;11:443-449. doi: 10.2147\/IJWH.S204275.\u003c\/p\u003e\n\u003cp\u003e[184] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[185] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[186] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[187] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[188] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[189] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[190] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[191] Calabrò RS, Naro A, De Luca R, Leonardi S, Russo M, Marra A, et al. PEALut efficacy in mild cognitive impairment: evidence from a SPECT case study. Aging Clin Exp Res. 2016 Dec;28(6):1279-1282. 2016 Jan 28. PMID: 26820462.\u003c\/p\u003e\n\u003cp\u003e[192] Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death Dis. 2014 Sep 11;5:e1419. doi: 10.1038\/cddis.2014.376.\u003c\/p\u003e\n\u003cp\u003e[193] Masek K, Perlík F, Klíma J, Kahlich R. Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur J Clin Pharmacol. 1974;7(6):415–419. doi:10.1007\/bf00560353.\u003c\/p\u003e\n\u003cp\u003e[194] Antonucci N, Cirillo A, Siniscalco D. Beneficial effects of palmitoylethanolamide on expressive language, cognition, and behaviors in autism: a report of two cases. Case Rep Psychiatry. 2015;2015:325061. doi:10.1155\/2015\/325061.\u003c\/p\u003e\n\u003cp\u003e[195] Caltagirone C, Cisari C, Schievano C, Di Paola R, Cordaro M, Bruschetta G et al. Co-ultramicronized palmitoylethanolamide\/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res. 2016 Feb;7(1):54-69. doi: 10.1007\/s12975-015-0440-8.\u003c\/p\u003e\n\u003cp\u003e[196] Mallard A, Briskey D, Richards A, Mills D, Rao A. The effect of orally dosed Levagen+™(palmitoylethanolamide) on exercise recovery in healthy males—a double-blind, randomized, placebo-controlled study. Nutrients. 2020 Mar;12(3):596.\u003c\/p\u003e\n\u003cp\u003e[197] Calabrò RS, Bramanti P. Occipital neuralgia responding to palmitoylethanolamide. Headache. 2017 Nov;57(10):E23-E24. doi: 10.1111\/head.12136.\u003c\/p\u003e\n\u003cp\u003e[198] Passavanti MB, Fiore M, Sansone P, Aurilio C, Pota V, Barbarisi M, et al. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms. BMC Anesthesiol. 2017 Dec 19;17(1):171. doi: 10.1186\/s12871-017-0461-9.\u003c\/p\u003e\n\u003cp\u003e[199] Ghazizadeh-Hashemi M, Ghajar A, Shalbafan MR, Ghazizadeh-Hashemi F, Afarideh M, Malekpour F, et al. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. J Affect Disord. 2018 May;232:127-133. doi:10.1016\/j.jad.2018.02.057.\u003c\/p\u003e\n\u003cp\u003e[200] Strobbe E, Cellini M, Campos EC. Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study. Invest Ophthalmol. 2013 Feb 1;54(2):968-73.\u003c\/p\u003e\n\u003cp\u003e[201] Bacci C, Cassetta G, Emanuele B, Berengo M. Randomized split-mouth study on postoperative effects of palmitoylethanolamide for impacted lower third molar surgery. ISRN Surg. 2011;2011:917350. doi: 10.5402\/2011\/917350.\u003c\/p\u003e\n\u003cp\u003e[202] Murina F, Graziottin A, Felice R, Radici G, Tognocchi C. Vestibulodynia: synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation. J Low Genit Tract Dis. 2013 Apr;17(2):111-6. doi: 10.1097\/LGT.0b013e3182652316.\u003c\/p\u003e\n\u003cp\u003e[203] Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437–442. doi:10.2147\/JPR.S32143.\u003c\/p\u003e\n\u003cp\u003e[204] Chirchiglia D, Chirchiglia P, Marotta R, Gallelli L. Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome. Int Med Case Rep J. 2019 Feb 15;12:39–42. doi:10.2147\/IMCRJ.S194403.\u003c\/p\u003e\n\u003cp\u003e[205] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[206] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[207] Passavanti MB, Fiore M, Sansone P, Aurilio C, Pota V, Barbarisi M, et al. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms. BMC Anesthesiol. 2017 Dec 19;17(1):171. doi: 10.1186\/s12871-017-0461-9.\u003c\/p\u003e\n\u003cp\u003e[208] Ghazizadeh-Hashemi M, Ghajar A, Shalbafan MR, Ghazizadeh-Hashemi F, Afarideh M, Malekpour F, et al. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. J Affect Disord. 2018 May;232:127-133. doi:10.1016\/j.jad.2018.02.057.\u003c\/p\u003e\n\u003cp\u003e[209] Chirchiglia D, Cione E, Caroleo MC, Wang M, Di Mizio G, Faedda N, et al. Effects of add-on ultramicronized N-palmitolethanolamide in patients suffering of migraine with aura: a pilot study. Front Neurol. 2018 Aug 17;9:674. doi:10.3389\/fneur.2018.00674.\u003c\/p\u003e\n\u003cp\u003e[210] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[211] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[212] Chirchiglia D, Della Torre A, Signorelli F, Volpentesta G, Guzzi G, Stroscio CA, et al. Administration of palmitoylethanolamide in combination with topiramate in the preventive treatment of nummular headache. Int Med Case Rep J. 2016 Jul 18;9:193–195. doi:10.2147\/IMCRJ.S106323.\u003c\/p\u003e\n\u003cp\u003e[213] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014 Apr;22(2):79-94. doi:10.1007\/s10787-013-0191-7.\u003c\/p\u003e\n\u003cp\u003e[214] Keppel Hesselink JM, de Boer T, Witkamp RF. Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common Cold. Int J Inflam. 2013;2013:151028. doi: 10.1155\/2013\/151028.\u003c\/p\u003e\n\u003cp\u003e[215] Assini A, Laricchia D, Pizzo R, Pandolfini L, Belletti M, Colucci M, et al. The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide: P1577. Eur J Neurol. 2010 Sep 17;12(3):295-295.\u003c\/p\u003e\n\u003cp\u003e[216] Coraci D, Loreti C, Granata G, Arezzo MF, Padua L. Carpal tunnel syndrome treatment with palmitoylethanolamide: neurophysiology and ultrasound show small changes in the median nerve. Rheumatol Int. 2018 Jul;38(7):1307-1309. doi:10.1007\/s00296-018-4064-7.\u003c\/p\u003e\n\u003cp\u003e[217] Faig-Martí J, Martínez-Catassús A. Use of palmitoylethanolamide in carpal tunnel syndrome: a prospective randomized study. J Orthop Traumatol. 2017 Dec;18(4):451-455. doi: 10.1007\/s10195-017-0453-z.\u003c\/p\u003e\n\u003cp\u003e[218] Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med. 2011 Apr;102(2):141-7. PMID: 21483401.\u003c\/p\u003e\n\u003cp\u003e[219] Calabrò RS, Naro A, De Luca R, Leonardi S, Russo M, Marra A, et al. PEALut efficacy in mild cognitive impairment: evidence from a SPECT case study. Aging Clin Exp Res. 2016 Dec;28(6):1279-1282. 2016 Jan 28. PMID: 26820462.\u003c\/p\u003e\n\u003cp\u003e[220] Ghazizadeh-Hashemi M, Ghajar A, Shalbafan MR, Ghazizadeh-Hashemi F, Afarideh M, Malekpour F, et al. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. J Affect Disord. 2018 May;232:127-133. doi:10.1016\/j.jad.2018.02.057.\u003c\/p\u003e\n\u003cp\u003e[221] Tartaglia E, Armentano M, Giugliano B, Sena T, Giuliano P, Loffredo C, et al. Effectiveness of the association N-palmitoylethanolamine and transpolydatin in the treatment of primary dysmenorrhea. J Pediatr Adolesc Gynecol. 2015 Dec;28(6):447-50. doi: 10.1016\/j.jpag.2014.12.011.\u003c\/p\u003e\n\u003cp\u003e[222] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. doi: 10.1155\/2014\/849623.\u003c\/p\u003e\n\u003cp\u003e[223] Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat. 2014;2014:854560. doi: 10.1155\/2014\/854560.\u003c\/p\u003e\n\u003cp\u003e[224] Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, et al. Effectiveness of the association micronized N-palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):82-6. doi: 10.1016\/j.ejogrb.2011.04.011.\u003c\/p\u003e\n\u003cp\u003e[225] Giugliano E, Cagnazzo E, Soave I, Lo Monte G, Wenger JM, Marci R. The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain. Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):209-13. doi: 10.1016\/j.ejogrb.2013.01.009.\u003c\/p\u003e\n\u003cp\u003e[226] Di Francesco A, Pizzigallo D. Use of micronized palmitoylethanolamide and trans-polydatin in chronic pelvic pain associated with endometriosis: an open-label study. Giornale Italiano di Ostetricia e Ginecologia CIC Edizioni Internazionali.2014 May 30;36(2):353-358.\u003c\/p\u003e\n\u003cp\u003e[227] Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015 Dec;4(2):169-78. doi:10.1007\/s40122-015-0038-6.\u003c\/p\u003e\n\u003cp\u003e[228] Schweiger V, Martini A, Bellamoli P, Donadello K, Schievano C, Balzo GD, et al. Ultramicronized palmitoylethanolamide(um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): retrospective observational study on 407 patients. CNS Neurol Disord Drug Targets. 2019;18(4):326-333. doi: 10.2174\/1871527318666190227205359.\u003c\/p\u003e\n\u003cp\u003e[229] Keppel Hesselink JM, Costagliola C, Fakhry J, Kopsky DJ. Palmitoylethanolamide, a natural retinoprotectant: its putative relevance for the treatment of glaucoma and diabetic retinopathy. J Ophthalmol. 2015;2015:430596. doi: 10.1155\/2015\/430596.\u003c\/p\u003e\n\u003cp\u003e[230] Domínguez CM, Martín AD, Ferrer FG, Puertas MI, Muro AL, González JM, et al. N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manag. 2012 Mar;2(2):119-24. doi:10.2217\/pmt.12.5.\u003c\/p\u003e\n\u003cp\u003e[231] Passavanti MB, Fiore M, Sansone P, Aurilio C, Pota V, Barbarisi M, et al. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms. BMC Anesthesiol. 2017 Dec 19;17(1):171. doi: 10.1186\/s12871-017-0461-9.\u003c\/p\u003e\n\u003cp\u003e[232] Desio P. Combination of oxycodone and palmitoylethanolamide for low back pain treatment. AMC. 2011;1(2):62–71.\u003c\/p\u003e\n\u003cp\u003e[233] Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20. PMID: 22229320.\u003c\/p\u003e\n\u003cp\u003e[234] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007\/s10787-019-00582-9.\u003c\/p\u003e\n\u003cp\u003e[235] Marini I, Lavinia Bartolucci M, Bortolotti F, Rosaria Gatto M, Alessandri Bonetti G. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012 Apr 1;26(2):99.\u003c\/p\u003e\n\u003cp\u003e[236] Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017 Jul;20(5):353-362. PMID: 28727699.\u003c\/p\u003e\n\u003cp\u003e[237] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012 Sep;13(9):1121-30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[238] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson's disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-713. doi: 10.2174\/1871527316666170321124949.\u003c\/p\u003e\n\u003cp\u003e[239] Domínguez CM, Martín AD, Ferrer FG, Puertas MI, Muro AL, González JM, et al. N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manag. 2012 Mar;2(2):119-24. doi:10.2217\/pmt.12.5.\u003c\/p\u003e\n\u003cp\u003e[240] Guida G, De Martino M, De Fabiani A, Canterieri L, Alexandre A, Vassallo GM, et al. Palmitoylethanolamide (Normast®) in chronic neuropathic pain due to compression lumbociatalgia: a multicenter clinical study. DOLOR. 2010:25(1):35-42.\u003c\/p\u003e\n\u003cp\u003e[241] Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015;8:729-734. doi:10.2147\/JPR.S93106.\u003c\/p\u003e\n\u003cp\u003e[242] Guida G, Cantieri L, Petrosino S. Reduction of the consumption of anti‐inflammatory drugs and analgesics in the treatment of chronic neuropathic pain in patients affected by compressive lumbociatalgia and in treatment with Normast® 300 mg. Pain. Clin \u0026amp; Thera Res 2010; 25(4):227‐234.\u003c\/p\u003e\n\u003cp\u003e[243] Caltagirone C, Cisari C, Schievano C, Di Paola R, Cordaro M, Bruschetta G, et al. Co-ultramicronized palmitoylethanolamide\/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res. 2016 Feb;7(1):54-69. doi: 10.1007\/s12975-015-0440-8.\u003c\/p\u003e\n\u003cp\u003e[244] Bacci C, Cassetta G, Emanuele B, Berengo M. Randomized split-mouth study on postoperative effects of palmitoylethanolamide for impacted lower third molar surgery. ISRN Surg. 2011;2011:917350. doi: 10.5402\/2011\/917350.\u003c\/p\u003e\n\u003cp\u003e[245] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Apr;13(2):428-38. doi: 10.1007\/s13311-016-0420-z.\u003c\/p\u003e\n\u003cp\u003e[246] Kopsky DJ, Hesselink JM. Multimodal stepped care approach with acupuncture and PPAR-α agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain. Acupunct Med. 2012 Mar;30(1):53-5. doi: 10.1136\/acupmed-2011-010119.\u003c\/p\u003e\n\u003cp\u003e[247] Murina F, Graziottin A, Felice R, Radici G, Tognocchi C. Vestibulodynia: synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation. J Low Genit Tract Dis. 2013 Apr;17(2):111-6. doi: 10.1097\/LGT.0b013e3182652316.\u003c\/p\u003e\n\u003cp\u003e[248] Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111\/bcp.13020.\u003c\/p\u003e\n\u003cp\u003e[249] Davis MP, Behm B, Mehta Z, Fernandez C. The potential benefits of palmitoylethanolamide in palliation: a qualitative systematic review. Am J Hosp Palliat Care. 2019 Dec;36(12):1134-1154. doi: 10.1177\/1049909119850807.\u003c\/p\u003e\n\u003cp\u003e[250] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012;13(9):1121–30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003cp\u003e[251] Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017 Jul;20(5):353-362. PMID: 28727699.\u003c\/p\u003e\n\u003cp\u003e[252] Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11–24.\u003c\/p\u003e\n\u003cp\u003e[253] Déciga-Campos M, Ramírez-Marín PM, López-Muñoz FJ. Synergistic antinociceptive interaction between palmitoylethanolamide and tramadol in the mouse formalin test. Eur J Pharmacol. 2015;765:68–74. doi:10.1016\/j.ejphar.2015.08.025.\u003c\/p\u003e\n\u003cp\u003e[254] Russo R, LoVerme J, La Rana G, D'Agostinoa G, Sassoa O, Calignano A, et al. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol. 2007;566(1-3):117–9. doi:10.1016\/j.ejphar.2007.03.007.\u003c\/p\u003e\n\u003cp\u003e[255] Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111\/bcp.13020.\u003c\/p\u003e\n\u003cp\u003e[256] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012;13(9):1121–30. doi:10.1111\/j.1526-4637.2012.01432.x.\u003c\/p\u003e\n\u003c!-- \/TABS --\u003e"}

Metagenics Bio Absorb PEA 42 caps

Product Description

PEA (Palmitoylethanolamide) With Endocannabinoid Action High Strength, Enhanced Absorption For Nerve Pain.

Metagenics Bio Absorb PEA 42 capsules (VegeCaps) 

  • Highly bioavailable (Palmitoylethanolamide) PEA for enhanced and superior absorption, using Levagen+ delivery system.
  • Exerts endocannabinoid-like actions, providing analgesic, neuroprotective and anti-inflammatory support.
  • Clinically trialled, sustainably sourced PEA for pain relief, including nerve pain in a convenient capsule form.

Metagenics Bio Absorb PEA available in Size: 42 VegeCaps

Metagenics Bio Absorb PEA is free from animal products, dairy protein, lactose, eggs, gluten, wheat, nuts, and soy protein.

Metagenics Bio Absorb PEA is free from artificial colours, flavours and preservatives. RSPO (Roundtable on Sustainable Palm Oil) certified.

Related products  

x